Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Venetoclax. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 known ✓ | P10415 | 20/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | BID | P55957 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | BAD | Q92934 | 1/20 | 1.00 |
| ▸ | NSD1 | Q96L73 | 1/20 | 1.00 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venetoclax SCHEMBL29390802 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29353714 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL29360081 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL523816 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278845 | 0.99 | BCL2 (0.99) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278892 | 0.99 | BCL2 (0.98) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| Venetoclax SCHEMBL19278891 | 0.99 | BCL2 (0.98) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038769 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16038376 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699816 | 0.98 | BCL2 (0.96) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2025-12-04 | — | — | US | claimed |
| US-20240277838-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2024-08-22 | — | — | US | claimed |
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250186451-A1 | METHODS OF TREATING CANCER WITH IAP ANTAGONIST COMPOUNDS AND COMBINATION THERAPIES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250152582-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4486352-A1 | METHODS OF TREATING CANCER WITH IAP ANTAGONIST COMPOUNDS AND COMBINATION THERAPIES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-01-08 | — | — | EP | disclosed |
| US-20240277838-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| JP-2024095793-A | COMBINATION THERAPY OF TYPE II ANTI-CD20 ANTIBODY WITH SELECTIVE BCL-2 INHIBITOR | ジェネンテック， インコーポレイテッド | 2024-07-10 | — | — | JP | disclosed |
| WO-2023168394-A1 | METHODS OF TREATING CANCER WITH IAP ANTAGONIST COMPOUNDS AND COMBINATION THERAPIES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-09-07 | — | — | WO | disclosed |
| US-11590128-B2 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor | GENENTECH, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220370441-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| EP-4031136-A1 | COMBINATION TREATMENT WITH A P53 REACTIVATOR AND AN INHIBITOR OF AN ANTIAPOPTOTIC BCL-2 FAMILY PROTEIN | Aprea Therapeutics AB (SE) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277838-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | ERBB2, BAK1, BCL2L2 | BCL2 4/4885BCL2L1 6/4885MCL1 22/4885 |
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | ERBB2, BAK1, BCL2L2 | BCL2 4/4885BCL2L1 6/4885MCL1 22/4885 |
| US-20250152582-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | BCL3, BAK1, BCL2L13 | BCL2 4/4885BCL2L1 7/4885MCL1 9/4885 |
| US-20250186451-A1 | METHODS OF TREATING CANCER WITH IAP ANTAGONIST COMPOUNDS AND COMBINATION THERAPIES | XIAP, BIRC5, BIRC2 | BCL2 55/4885BCL2L1 36/4885MCL1 7/4885 |
| US-20220370441-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | BCL3, BAK1, BCL2L13 | BCL2 4/4885BCL2L1 7/4885MCL1 9/4885 |
| US-11590128-B2 | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor | BCL3, BAK1, BCL2L13 | BCL2 4/4885BCL2L1 7/4885MCL1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.